{"organizations": [], "uuid": "a62f84925af3b2274140e6e7298fbead220bb04f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180409.html", "section_title": "Archive News &amp; Video for Monday, 09 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-abbvie-says-upadacitinib-met-all-p/brief-abbvie-says-upadacitinib-met-all-primary-and-ranked-secondary-endpoints-in-phase-3-study-in-rheumatoid-arthritis-idUSFWN1RM0N7", "country": "US", "domain_rank": 408, "title": "BRIEF-AbbVie Says Upadacitinib Met All Primary And Ranked Secondary Endpoints In Phase 3 Study In Rheumatoid Arthritis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-09T21:05:00.000+03:00", "replies_count": 0, "uuid": "a62f84925af3b2274140e6e7298fbead220bb04f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-abbvie-says-upadacitinib-met-all-p/brief-abbvie-says-upadacitinib-met-all-primary-and-ranked-secondary-endpoints-in-phase-3-study-in-rheumatoid-arthritis-idUSFWN1RM0N7", "ord_in_thread": 0, "title": "BRIEF-AbbVie Says Upadacitinib Met All Primary And Ranked Secondary Endpoints In Phase 3 Study In Rheumatoid Arthritis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "negative"}, {"name": "upadacitinib", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9 (Reuters) - AbbVie Inc:\n* UPADACITINIB MEETS ALL PRIMARY AND RANKED SECONDARY ENDPOINTS INCLUDING SUPERIORITY VERSUS ADALIMUMAB IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS\n* ALL RANKED SECONDARY ENDPOINTS ALSO MET IN PHASE 3 STUDY IN RHEUMATOID ARTHRITIS\n* PLANS GLOBAL REGULATORY SUBMISSIONS FOR UPADACITINIB IN RHEUMATOID ARTHRITIS IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-09T21:05:00.000+03:00", "crawled": "2018-04-10T12:50:52.007+03:00", "highlightTitle": ""}